New! Sign up for our free email newsletter.
Science News
from research organizations

Study shows different approach after progression in non-small cell lung cancer patients

Date:
November 15, 2012
Source:
International Association for the Study of Lung Cancer
Summary:
A new study shows that other approaches to overcome acquired resistance should be considered.
Share:
FULL STORY

Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, respectively. However, progression inevitably occurs. When it does, having no clear guidelines and/or indications, most patients are treated with chemotherapy.

A new study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that other approaches to overcome acquired resistance should be considered.

Researchers looked at NSCLC patients with histologically confirmed ALK rearrangements or EGFR mutations who were treated with crizotinib or erlotinib at the University of Colorado Cancer Center between May 2005 and December 2011.

Of the 51 patients whose cancer grew eventually on the targeted drugs, 25 were deemed suitable for local ablative therapy radiotherapy or surgery) to the site of progression, and then continued on the same drug. The use of this strategy prolonged the duration of disease control by the drug by 6.2 months, on top of the median of 9.8 months initial disease control. The benefit was most marked in patients who only experienced isolated growth in the brain -- this group had another median 7.1 months of disease control before further growth either in the body and brain.

While the authors point out study limitations and the need for further research, they say their experience suggests that when NSCLC patients with EGFR mutations or ALK rearrangements "progress on erlotinib or crizotinib, respectively, and the progression occurs in only a limited number of sites (oligoprogressive disease) it may be reasonable to consider LAT to the sites of progression and continuation of the TKI."

The lead author of this work is IASLC member Dr. Andrew Weickhardt. Co-authors include IASLC members Dr. Paul Bunn, Dr. Dara Aisner, Dr. Laurie Gaspar, Dr. Robert Doebele and Dr. Ross Camidge.


Story Source:

Materials provided by International Association for the Study of Lung Cancer. Note: Content may be edited for style and length.


Cite This Page:

International Association for the Study of Lung Cancer. "Study shows different approach after progression in non-small cell lung cancer patients." ScienceDaily. ScienceDaily, 15 November 2012. <www.sciencedaily.com/releases/2012/11/121115133756.htm>.
International Association for the Study of Lung Cancer. (2012, November 15). Study shows different approach after progression in non-small cell lung cancer patients. ScienceDaily. Retrieved March 18, 2024 from www.sciencedaily.com/releases/2012/11/121115133756.htm
International Association for the Study of Lung Cancer. "Study shows different approach after progression in non-small cell lung cancer patients." ScienceDaily. www.sciencedaily.com/releases/2012/11/121115133756.htm (accessed March 18, 2024).

Explore More

from ScienceDaily

RELATED STORIES